Kane Biotech (KNBIF) 0.0246 $KNBIF
Kane Biotech Announces Financing Update
Marketwired - Fri Aug 21, 6:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) ("Kane Biotech" or the "Company"
, a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, wishes to announce that it is terminating its previously announced private placement to certain U.S. investors of up to 16,100,000 units of Kane Biotech for gross proceeds of up to $1,127,000. The Company will be pursuing other financing later this year.
KNE.VN: 0.030 (unch)
Kane Biotech and the U.S. Army Institute of Surgical Research Sign Cooperative Research and Development Agreement Extension
Marketwired - Tue Aug 04, 6:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce a three year Cooperative Research and Development Agreement (CRADA) extension has been signed with the U.S. Army Institute of Surgical Research (USAISR) in Fort Sam Houston, Texas.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Financing and Business Update
Marketwired - Tue Jul 28, 6:00AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) ("Kane Biotech" or the "Company", a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, wishes to announce the following financing initiatives and updates regarding the status of its business.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Jun 25, 10:49AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" announced that on June 23, 2015, it issued 254,178 common shares of the Corporation ("Common Shares" in payment of $12,708.91 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at June 18, 2015. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on June 23, 2015. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Board Members
Marketwired - Thu Jun 25, 10:42AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 22, 2015 (the "Meeting", the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard and Mark Ahrens-Townsend. Each Director is to serve for a term of one year or until their successors are elected or appointed.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Joint Development Agreement and Channel Expansion
Marketwired - Wed May 13, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's current focus is on the animal oral care market.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Change in Executive Leadership
Marketwired - Mon May 11, 6:31AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.
KNE.VN: 0.030 (unch)
Kane Biotech Summarizes Compelling Oral Care Study Results
Marketwired - Thu Mar 26, 7:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.
KNE.VN: 0.030 (unch)
Kane Biotech Introduces bluestem(TM)
Marketwired - Thu Feb 12, 8:26AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms announces that it will be introducing the company's bluestem pet oral care brand in the over the counter (OTC) retail market.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Financing Update
Marketwired - Fri Aug 21, 6:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) ("Kane Biotech" or the "Company"
, a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, wishes to announce that it is terminating its previously announced private placement to certain U.S. investors of up to 16,100,000 units of Kane Biotech for gross proceeds of up to $1,127,000. The Company will be pursuing other financing later this year. KNE.VN: 0.030 (unch)
Kane Biotech and the U.S. Army Institute of Surgical Research Sign Cooperative Research and Development Agreement Extension
Marketwired - Tue Aug 04, 6:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce a three year Cooperative Research and Development Agreement (CRADA) extension has been signed with the U.S. Army Institute of Surgical Research (USAISR) in Fort Sam Houston, Texas.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Financing and Business Update
Marketwired - Tue Jul 28, 6:00AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) ("Kane Biotech" or the "Company"
, a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, wishes to announce the following financing initiatives and updates regarding the status of its business. KNE.VN: 0.030 (unch)
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Jun 25, 10:49AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
announced that on June 23, 2015, it issued 254,178 common shares of the Corporation ("Common Shares" in payment of $12,708.91 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at June 18, 2015. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on June 23, 2015. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies. KNE.VN: 0.030 (unch)
Kane Biotech Announces Board Members
Marketwired - Thu Jun 25, 10:42AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 22, 2015 (the "Meeting"
, the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard and Mark Ahrens-Townsend. Each Director is to serve for a term of one year or until their successors are elected or appointed. KNE.VN: 0.030 (unch)
Kane Biotech Announces Joint Development Agreement and Channel Expansion
Marketwired - Wed May 13, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's current focus is on the animal oral care market.
KNE.VN: 0.030 (unch)
Kane Biotech Announces Change in Executive Leadership
Marketwired - Mon May 11, 6:31AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.
KNE.VN: 0.030 (unch)
Kane Biotech Summarizes Compelling Oral Care Study Results
Marketwired - Thu Mar 26, 7:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.
KNE.VN: 0.030 (unch)
Kane Biotech Introduces bluestem(TM)
Marketwired - Thu Feb 12, 8:26AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms announces that it will be introducing the company's bluestem pet oral care brand in the over the counter (OTC) retail market.
KNE.VN: 0.030 (unch)
